How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 25 07 2019
accepted: 03 09 2019
revised: 02 09 2019
pubmed: 11 9 2019
medline: 15 4 2020
entrez: 11 9 2019
Statut: ppublish

Résumé

Patients with cervical dystonia (CD) typically require regular injections of botulinum toxin to maintain symptomatic control. We aimed to document long-term patient satisfaction with CD symptom control in a large cohort of patients treated in routine practice. This was a prospective, international, observational study (NCT01753349) following the course of adult CD treated with botulinum neurotoxin type A (BoNT-A) over 3 years. A comprehensive clinical assessment status was performed at each injection visit and subjects reported satisfaction in two ways: satisfaction with symptom control at peak effect and at the end of treatment cycle. Subject satisfaction remained relatively stable from the first to the last injection visit. At 3 years, 89.9% of subjects reported satisfaction with symptom control at peak effect and 55.6% reported satisfaction with symptom control at end of treatment cycle. By contrast, objective ratings of CD severity showed an overall reduction over 3 years. Mean ± SD Toronto Western Spasmodic Rating Scale (TWSTRS) Total scores (clinician assessed at end of treatment cycle) decreased from 31.59 ± 13.04 at baseline to 24.49 ± 12.43 at 3 years (mean ± SD reduction from baseline of - 6.97 ± 11.56 points). Tsui scale scores also showed gradual improvement; the percent of subjects with a tremor component score of 4 reduced from 12.4% at baseline to 8.1% at 3 years. Despite objective clinical improvements over 3 years, subject satisfaction with symptom control remained relatively constant, indicating that factors other than symptom control also play a role in patient satisfaction.

Sections du résumé

BACKGROUND BACKGROUND
Patients with cervical dystonia (CD) typically require regular injections of botulinum toxin to maintain symptomatic control. We aimed to document long-term patient satisfaction with CD symptom control in a large cohort of patients treated in routine practice.
METHODS METHODS
This was a prospective, international, observational study (NCT01753349) following the course of adult CD treated with botulinum neurotoxin type A (BoNT-A) over 3 years. A comprehensive clinical assessment status was performed at each injection visit and subjects reported satisfaction in two ways: satisfaction with symptom control at peak effect and at the end of treatment cycle.
RESULTS RESULTS
Subject satisfaction remained relatively stable from the first to the last injection visit. At 3 years, 89.9% of subjects reported satisfaction with symptom control at peak effect and 55.6% reported satisfaction with symptom control at end of treatment cycle. By contrast, objective ratings of CD severity showed an overall reduction over 3 years. Mean ± SD Toronto Western Spasmodic Rating Scale (TWSTRS) Total scores (clinician assessed at end of treatment cycle) decreased from 31.59 ± 13.04 at baseline to 24.49 ± 12.43 at 3 years (mean ± SD reduction from baseline of - 6.97 ± 11.56 points). Tsui scale scores also showed gradual improvement; the percent of subjects with a tremor component score of 4 reduced from 12.4% at baseline to 8.1% at 3 years.
CONCLUSIONS CONCLUSIONS
Despite objective clinical improvements over 3 years, subject satisfaction with symptom control remained relatively constant, indicating that factors other than symptom control also play a role in patient satisfaction.

Identifiants

pubmed: 31501975
doi: 10.1007/s00415-019-09527-2
pii: 10.1007/s00415-019-09527-2
pmc: PMC6851034
doi:

Substances chimiques

Neuromuscular Agents 0
Botulinum Toxins, Type A EC 3.4.24.69

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

3038-3046

Investigateurs

A Abdulnayef (A)
N U Adatepe (NU)
M A Araujo Leite (MA)
S Badarny (S)
O Bajenaru (O)
M Bares (M)
P Bejjani (P)
B Bergmans (B)
R Bhidayasiri (R)
H Bozic (H)
F E Cardoso Costa (FE)
C Carlstrom (C)
G Castelnovo (G)
M H Chang (MH)
Y Y Chang (YY)
T M Chung (TM)
M Coletti-Moja (M)
V Delvaux (V)
P Dioszhegy (P)
O Dogu (O)
W Duzynski (W)
E Ehler (E)
L Espinosa Sierra (L)
G Fabbrini (G)
J Ferreira (J)
A Ferreira Valadas (A)
C Foresti (C)
P Girlanda (P)
K J Goh (KJ)
A Graca Velon (A)
S Grill (S)
T Gurevitch (T)
M Hadidi (M)
M A Hamimed (MA)
A Hamri (A)
T Harrower (T)
S Hassin (S)
P Hedera (P)
J F J G Hernandez (JFJG)
J Hernandez Franco (J)
B Ho (B)
S L Ho (SL)
A Hughes (A)
T Ilic (T)
J S Inshasi (JS)
C W Ip (CW)
S Jamieson (S)
R D G Jamora (RDG)
R Jech (R)
B S Jeon (BS)
A Kaminska (A)
M Karpova (M)
D Khasanova (D)
J M Kim (JM)
J W Kim (JW)
C Y Kok (CY)
A Korenko (A)
J Korv (J)
S Koussa (S)
T Kovacs (T)
A Kreisler (A)
P Krystkowiak (P)
W Kumthornthip (W)
C H Lin (CH)
F Lundin (F)
G Lus (G)
M Magalhaes (M)
A N Masmoudi (AN)
R Mercelis (R)
A Misbahuddin (A)
C Moebius (C)
B Mohammadi (B)
B Nazem (B)
K Ng (K)
G Nurlu (G)
J Nyberg (J)
D Nyholm (D)
S Ochudlo (S)
P Otruba (P)
R Pfister (R)
Z Pirtosek (Z)
D Pokhabov (D)
S Quinones Aguilar (S)
G Quinones Canales (G)
S Raghev (S)
H Rickmann (H)
M Romano (M)
R L Rosales (RL)
I Rubanovits (I)
V Santilli (V)
L Schoels (L)
M Simonetta-Moreau (M)
M A Simu (MA)
Y H Sohn (YH)
S Soulayrol (S)
I Supe (I)
M Svetel (M)
T Sycha (T)
E K Tan (EK)
S Timerbaeva (S)
A B Tokcaer (AB)
R Trosch (R)
V Tugnoli (V)
V Tumas (V)
C Van der Linden (C)
A Vetra (A)
C Vial (C)
E Vidry (E)
D Williams (D)
S Wimalaratna (S)
C Yiannikas (C)

Commentaires et corrections

Type : ErratumIn

Références

PLoS One. 2017 Feb 7;12(2):e0170988
pubmed: 28170443
J Neurol. 2002 Jul;249(7):842-6
pubmed: 12140667
Handb Clin Neurol. 2011;100:481-511
pubmed: 21496604
Mov Disord. 2000 Jan;15(1):150-3
pubmed: 10634256
Tremor Other Hyperkinet Mov (N Y). 2013 Nov 04;3:
pubmed: 24255801
Mov Disord. 2011 Jun;26(7):1206-17
pubmed: 21484874
Neurology. 2000;55(12 Suppl 5):S2-8
pubmed: 11188980
J Neurol. 2018 Feb;265(2):402-409
pubmed: 29270685
Parkinsonism Relat Disord. 2018 Jul;52:94-97
pubmed: 29530726
Value Health. 2012 May;15(3):401-3
pubmed: 22583448
Neurotox Res. 2012 Nov;22(4):265-73
pubmed: 22359151
J Med Econ. 2012;15(3):419-23
pubmed: 22208596
Mov Disord. 1991;6(2):119-26
pubmed: 2057004
J Neurol. 2015;262(4):837-48
pubmed: 25605434
Arch Neurol. 1990 May;47(5):548-52
pubmed: 2334302
Toxins (Basel). 2013 Apr 23;5(4):776-83
pubmed: 23612751
BMJ. 2010 Jun 21;340:c2921
pubmed: 20566597
Neurology. 2016 May 10;86(19):1818-26
pubmed: 27164716
Neurol Clin. 2008 May;26 Suppl 1:23-42
pubmed: 18603166
Funct Neurol. 2012 Oct-Dec;27(4):225-30
pubmed: 23597436
Eur J Neurol. 2011 Jan;18(1):5-18
pubmed: 20482602
Neurol Res. 2009 Jun;31(5):463-6
pubmed: 19278576
Toxins (Basel). 2013 Feb 04;5(2):249-66
pubmed: 23381141
J Neurol Neurosurg Psychiatry. 2002 May;72(5):608-14
pubmed: 11971047
Eur J Neurol. 2005 Mar;12(3):163-70
pubmed: 15693803
Clin Neurol Neurosurg. 2009 Feb;111(2):161-4
pubmed: 18995953
Mov Disord. 2004 Mar;19(3):303-8
pubmed: 15022184
Complement Ther Clin Pract. 2005 Nov;11(4):262-5
pubmed: 16290897
Lancet. 1986 Aug 2;2(8501):245-7
pubmed: 2874278

Auteurs

Carlo Colosimo (C)

Department of Neurology, Santa Maria University Hospital, Viale Tristano di Joannuccio 1, 05100, Terni, Italy. carlo.colosimo@uniroma1.it.

David Charles (D)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Vijay P Misra (VP)

Department of Neurology, Imperial College Healthcare NHS Trust, London, UK.

Pascal Maisonobe (P)

Ipsen Pharma, Boulogne-Billancourt, France.

Savary Om (S)

Ipsen Pharma, Boulogne-Billancourt, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH